• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Journal articles
    • View Item
    • Home
    • Griffith Research Online
    • Journal articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Pregabalin: Dose-response relationship in generalized anxiety disorder

    Thumbnail
    View/Open
    79389_1.pdf (93.89Kb)
    Author
    Boschen, Mark
    Year published
    2012
    Metadata
    Show full item record
    Abstract
    Introduction: Pregabalin is a structural analogue of the inhibitory neurotransmitter GABA. Although pregabalin has demonstrated efficacy in the treatment of generalized anxiety disorder (GAD) in a number of randomized controlled trials, there is little published data on the optimal dose for treating this condition. The objective of the current study was to examine the dose-response relationship for treatment of GAD with pregabalin. Method: The current study pools results from previous fixed-dose treatment trials of GAD with pregabalin and uses curve-fitting statistical procedures to generate curvilinear regression ...
    View more >
    Introduction: Pregabalin is a structural analogue of the inhibitory neurotransmitter GABA. Although pregabalin has demonstrated efficacy in the treatment of generalized anxiety disorder (GAD) in a number of randomized controlled trials, there is little published data on the optimal dose for treating this condition. The objective of the current study was to examine the dose-response relationship for treatment of GAD with pregabalin. Method: The current study pools results from previous fixed-dose treatment trials of GAD with pregabalin and uses curve-fitting statistical procedures to generate curvilinear regression lines as a synthesis of previous dose-response information. Results: Peak reduction in anxiety symptoms was observed to occur at a dose of approximately 450 mg/day, with a small reduction in treatment effect beyond this dose. Treatment effect on psychic anxiety symptoms reached a peak at approximately 400 mg, with a reduction in efficacy beyond this dose. Somatic anxiety symptoms showed continued increase in therapeutic effect up to the maximum dose of 600 mg/day. Discussion: Implications for psychiatric practice, limitations of the methodology and avenues for future research are discussed.
    View less >
    Journal Title
    Pharmacopsychiatry
    Volume
    45
    Issue
    2
    DOI
    https://doi.org/10.1055/s-0031-1291176
    Copyright Statement
    © 2012 Georg Thieme Verlag. This is the author-manuscript version of the paper. Reproduced in accordance with the copyright policy of the publisher. The definitive version is available at www.thieme-connect.com
    Subject
    Health, Clinical and Counselling Psychology
    Basic Pharmacology
    Publication URI
    http://hdl.handle.net/10072/47705
    Collection
    • Journal articles

    Footer

    Social media

    • Facebook
    • Twitter
    • YouTube
    • Instagram
    • Linkedin
    First peoples of Australia
    • Aboriginal
    • Torres Strait Islander

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane
    • Australia